Skip to content

A randomized double-blind controlled clinical study on the improvement effect of probiotics on symptoms in patients with prediabetes

A randomized double-blind controlled clinical study on the improvement effect of probiotics on symptoms in patients with prediabetes

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500099118
Enrollment
Unknown
Registered
2025-03-18
Start date
2025-04-01
Completion date
Unknown
Last updated
2025-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prediabetes

Interventions

Bifidobacterium longum CCFM1113 group:Bifidobacterium longum CCFM1113
Bifidobacterium longum CCFM1113 compound formula set with Bifidobacterium juvenile CCFM1386 group:Bifidobacterium longum CCFM1113 compound formula set with Bifidobacterium juvenile CCFM1386
Placebo group:Placebo

Sponsors

Shanghai Changzheng Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Abnormal fasting blood glucose (IFG): 6.1< = fasting blood glucose (mmol/L) < 7.0; 2. Impaired glucose tolerance (IGT): 7.8 < = 2 hours of blood glucose (mmol/L) < 11.1 after the test subject took a liquid containing 75 g of glucose for two hours; 3. Abnormal glycosylated hemoglobin (HbA1c): 5.7<=HbA1c (%)<6.5; 4. Meet any of the 1-3 criteria and do not meet the diagnostic criteria for diabetes; 5. Age 18-75 years old, gender is not limited.

Exclusion criteria

Exclusion criteria: 1. Have been diagnosed with diabetes mellitus or have used any hypoglycemic drugs; 2. People who suffer from diseases that cause elevated blood sugar or take drugs that affect blood sugar; 3. Patients with secondary obesity, including diseases such as hypothyroidism or long-term use of drugs that cause obesity; 4. Pregnant or lactating females; 5. Unable, unwilling, or unwilling to comply with study requirements, including lifestyle modifications, return visits, and subject duties; 6. Taking glucocorticoids, antibiotics, prebiotics, probiotics, vitamin supplements, and any other drugs that may interfere with microbiome analysis within 4 weeks prior to enrollment; 7. Allergy or intolerance to the ingredients of the experimental probiotic product.

Design outcomes

Primary

MeasureTime frame
Glycated Hemoglobin A1c, HbA1c;

Secondary

MeasureTime frame
Fasting blood glucose;Fecal flora;Continuous blood glucose;Fasting insulin;BMI;Waist-hip ratio;Blood pressure;Blood lipids;Body composition;Liver Elasticity Imaging;

Countries

China

Contacts

Public ContactLi Juan

Shanghai Changzheng Hospital

yyk3020@163.com+86 139 1795 7979

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026